The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013

Soliman, Ahmed M.; Yang, Hongbo; Du, E.X.; Kelkar, Sneha S.; Winkel, Craig A.

doi:10.1016/j.ajog.2015.03.019

Cited by 87 publications

(84 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…AAW, however, disproportionately discussed challenges with inadequate health insurance coverage as compared to women of other racial/ethnic groups. Previous studies have examined the direct and indirect costs of fibroids at the national level, however few have examined this burden at the individual level [4, 5, 14]. Our study not only revealed the continued insurance challenges that women with fibroids experience but also highlights their day-to-day cost as demonstrated by the comments that women made about paying for costly hygiene related products and diagnostic testing.…”

Section: Discussionmentioning

confidence: 76%

Racial/Ethnic Differences in Women’s Experiences with Symptomatic Uterine Fibroids: a Qualitative Assessment

Sengoba¹,

Ghant

Okeigwe³

et al. 2016

J. Racial and Ethnic Health Disparities

View full text Add to dashboard Cite

Objective To determine racial/ethnic differences in treatment experiences and expectations among women with fibroids. Methods Sixty women with symptomatic uterine fibroids completed semi-structured interviews, demographic surveys and a health literacy assessment. Participants were recruited from community-based organizations and health care organizations. Data from interviews were analyzed using a grounded theory approach. Three coders identified major themes and subthemes. Results The kappa (κ) amongst coders was 0.94. The mean age of participants was 43.0 ± 6.8 (mean ± SD). 61.7% of subjects were African-American (AAW), 25.0% were Non-Hispanic White (WW), 8.3% were Hispanic (HW) and 5.0% were Asian (ASW). When considering treatment options, AAW were more likely to want a permanent intervention. They were also more likely to demonstrate an aversion toward conventional treatments. Of the women who received a surgical intervention, AAW were also more likely to have had a difficult recovery and to be dissatisfied with their treatment. Finally, AAW disproportionately expressed concern regarding financial challenges. Conclusions AAW have high treatment expectations, have more financial obstacles, and are less satisfied with their treatment outcomes than women of other racial/ethnic groups. Our findings suggest a need to create targeted patient interventions and education to ameliorate these disparities in experience.

show abstract

Section: Discussionmentioning

confidence: 76%

Racial/Ethnic Differences in Women’s Experiences with Symptomatic Uterine Fibroids: a Qualitative Assessment

Sengoba¹,

Ghant

Okeigwe³

et al. 2016

J. Racial and Ethnic Health Disparities

View full text Add to dashboard Cite

show abstract

“…The high prevalence of fibroids has a profound impact on health care costs worldwide. Studies have estimated annual direct and indirect costs related to uterine fibroids to be as high as US $34.4 billion in the United States, and total annual costs related to hospital admissions of US $348 million in Germany, US $120 million in France, and US $86 million in England . Further cost analysis studies are needed to better describe the economic burden of this condition in other geographic areas such as Africa, Asia, and Latin America.…”

Section: Introductionmentioning

confidence: 99%

Epidemiology and management of uterine fibroids

Giuliani

As‐Sanie

Marsh

2020

Intl J Gynecology & Obste

357

286

View full text Add to dashboard Cite

Uterine leiomyomas are one of the most common and yet understudied diseases in women. These tumors, commonly known as fibroids, affect women mainly during their reproductive years and are diagnosed in up to 70% of white women and more than 80% of women of African ancestry during their lifetime. This disease has a profound impact on health care delivery and costs worldwide. Though most women with fibroids are asymptomatic, approximately 30% of them will present with severe symptoms which can include abnormal uterine bleeding, anemia, pelvic pain and pressure, back pain, urinary frequency, constipation, or infertility, and will require intervention. Furthermore, fibroids have been associated with poor obstetrical outcomes. The current options for symptomatic fibroid treatment include expectant, medical, and surgical management, and interventional radiology procedures. This article reviews the recent progress and available management strategies for uterine fibroids and highlights areas where further research is needed to find new therapeutic targets and better personalize treatments.

show abstract

“…Several studies have documented how uterine fibroids and their associated symptoms may significantly impair a woman’s health-related quality of life (HRQL) 2,14. Uterine fibroids are associated with a significant economic burden as well; total annual costs have been estimated to be $6 to $34 billion in the US 15,16…”

Section: Introductionmentioning

confidence: 99%

Patient-reported prevalence and symptomatic burden of uterine fibroids among women in the United States: findings from a cross-sectional survey analysis

Fuldeore¹,

Soliman²

2017

IJWH

View full text Add to dashboard Cite

PurposeTo estimate the prevalence of women diagnosed with uterine fibroids and the associated symptom burden in the US.Patients and methodsResponses of women aged 18–54 years, who completed an online survey, were analyzed. Data were weighted based on age, education, race, geographic region, income, and propensity score to derive national estimates of the prevalence of women diagnosed with uterine fibroids and associated symptom burden. Weighted means and percentages were reported. Prevalence across age and ethnic groups was examined. Symptom burden among women with and without uterine fibroids was compared using weighted logistic regressions.ResultsOf 59,411 respondents who met study inclusion criteria, 7.7% reported receiving a diagnosis of uterine fibroids. Of these, 5,670 women (1,402 in the uterine fibroid group and 4,268 in the control group) were excluded from analysis because they had a hysterectomy. Among the non-hysterectomized study participants, 3,031 self-reported a diagnosis of uterine fibroids (prevalence: 5.8%, 95% confidence interval [CI]: 5.5%–6.1%); prevalence increased as women aged and was greatest in the 50–54 age group (11.4%; 95% CI: 10.4%–12.4%). In addition, prevalence was greater in black vs white women (9.8%; 95% CI: 8.7%–11.0% vs 5.4%; 95% CI: 5.1%–5.7%). A greater percentage of women with uterine fibroids (vs those without) experienced severe heavy menstrual bleeding (16.7% vs 7.7%), severe constipation/bloating/diarrhea (7.7% vs 4.7%), severe passage of clots (6.7% vs 2.4%), severe spotting/bleeding between periods (1.7% vs 1.0%), and severe pelvic pressure (1.6% vs 0.6%). Among uterine fibroid patients with these typical uterine fibroid-related symptoms, 56.4%, 32.3%, 26.4%, 25.8%, and 20.4% reported heavy menstrual bleeding, passage of clots, spotting/bleeding between periods, constipation/bloating/diarrhea, and pelvic pressure, respectively, as extremely bothersome.ConclusionUterine fibroids impose a heavy burden on women aged 18–54 years in the US.

show abstract

The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013

Cited by 87 publications

References 39 publications

Racial/Ethnic Differences in Women’s Experiences with Symptomatic Uterine Fibroids: a Qualitative Assessment

Racial/Ethnic Differences in Women’s Experiences with Symptomatic Uterine Fibroids: a Qualitative Assessment

Epidemiology and management of uterine fibroids

Patient-reported prevalence and symptomatic burden of uterine fibroids among women in the United States: findings from a cross-sectional survey analysis

Contact Info

Product

Resources

About